SFM
Sphera Funds Management Portfolio holdings
AUM
$382M
This Quarter Return
+2.74%
1 Year Return
+0.41%
3 Year Return
+99.29%
5 Year Return
+177.09%
10 Year Return
+575.73%
AUM
$611M
AUM Growth
+$611M
(-0.38%)
Cap. Flow
-$234M
Cap. Flow
% of AUM
-38.33%
Top 10 Holdings %
Top 10 Hldgs %
32.55%
Holding
133
New
19
Increased
27
Reduced
41
Closed
21
Top Buys
| 1 |
Teva Pharmaceuticals
TEVA
|
$24.2M |
| 2 |
Nova
NVMI
|
$10.8M |
| 3 |
Viking Therapeutics
VKTX
|
$8.42M |
| 4 |
Check Point Software Technologies
CHKP
|
$7.75M |
| 5 |
Biohaven
BHVN
|
$6.66M |
Top Sells
| 1 |
Broadcom
AVGO
|
$30.5M |
| 2 |
Kezar Life Sciences
KZR
|
$14.3M |
| 3 |
Salesforce
CRM
|
$8.64M |
| 4 |
Cytokinetics
CYTK
|
$8.44M |
| 5 |
Praxis Precision Medicines
PRAX
|
$7.54M |
Sector Composition
| 1 | Healthcare | 71.97% |
| 2 | Technology | 19.72% |
| 3 | Consumer Discretionary | 3.62% |
| 4 | Communication Services | 3.05% |
| 5 | Utilities | 0.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Perspective Therapeutics
CATX
$251M
| $7.87M | 1.25% |
589,295
-197,614
| -25% | -$2.64M |
|
|
27
Check Point Software Technologies
CHKP
$20.6B
| $7.75M | 1.23% |
+40,215
| New | +$7.75M |
|
28
AbbVie
ABBV
$374B
| $7.5M | 1.19% |
38,000
| – | – |
|
29
Merus
MRUS
$5.04B
| $7.38M | 1.17% |
147,633
| – | – |
|
30
Enphase Energy
ENPH
$4.85B
| $7.26M | 1.16% |
64,224
+7,432
| +13% | +$840K |
|
31
Merck
MRK
$210B
| $6.77M | 1.08% |
59,600
| – | – |
|
|
32
Biohaven
BHVN
$1.71B
| $6.66M | 1.06% |
+133,323
| New | +$6.66M |
|
33
SentinelOne
S
$6.01B
| $6.62M | 1.05% |
276,554
-7,250
| -3% | -$173K |
|
34
Marvell Technology
MRVL
$53.7B
| $6.32M | 1.01% |
87,611
+67,611
| +338% | +$4.88M |
|
|
INZY
35
DELISTED
Inozyme Pharma
INZY
| $6.23M | 0.99% |
1,191,140
-271,584
| -19% | -$1.42M |
|
36
Apellis Pharmaceuticals
APLS
$3.51B
| $6.23M | 0.99% |
+215,873
| New | +$6.23M |
|
37
Skye Bioscience
SKYE
$104M
| $6.11M | 0.97% |
1,563,522
+265,210
| +20% | +$1.04M |
|
38
Intellia Therapeutics
NTLA
$1.26B
| $5.98M | 0.95% |
291,080
+151,661
| +109% | +$3.12M |
|
39
Rezolute
RZLT
$630M
| $5.81M | 0.92% |
1,196,938
-511,061
| -30% | -$2.48M |
|
40
Novartis
NVS
$248B
| $5.75M | 0.92% |
50,000
| – | – |
|
41
WIX.com
WIX
$8.05B
| $5.73M | 0.91% |
34,253
+9,076
| +36% | +$1.52M |
|
|
VIGL
42
DELISTED
Vigil Neuroscience
VIGL
| $5.6M | 0.89% |
1,647,604
-44,562
| -3% | -$152K |
|
43
Day One Biopharmaceuticals
DAWN
$766M
| $4.84M | 0.77% |
347,627
| – | – |
|
44
Biogen
BIIB
$20.8B
| $4.74M | 0.75% |
24,455
-22,957
| -48% | -$4.45M |
|
45
PTC Therapeutics
PTCT
$4.41B
| $4.39M | 0.7% |
118,345
+24,027
| +25% | +$891K |
|
46
Rocket Pharmaceuticals
RCKT
$358M
| $4.28M | 0.68% |
231,792
+24,859
| +12% | +$459K |
|
47
GSK
GSK
$79.3B
| $4.09M | 0.65% |
100,000
| – | – |
|
48
89bio
ETNB
$1.37B
| $3.97M | 0.63% |
536,547
+10,000
| +2% | +$74K |
|
49
Acadia Pharmaceuticals
ACAD
$4.34B
| $3.88M | 0.62% |
252,539
-75,000
| -23% | -$1.15M |
|
50
Jasper Therapeutics
JSPR
$44.2M
| $3.56M | 0.57% |
189,270
-264,957
| -58% | -$4.98M |
|